FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Athos Gianella-Borradori

Research Profile

Chemicals & Drugs

Physiology

Concepts & Ideas

Anatomy

Tumor Cell Line

Procedures

Clinical Trials as Topic

Disorders

Living Beings

Mouse

Co-author Network

Publications

TOP 3
Christophe Le Tourneau; Sandrine Faivre; Valérie Laurence; Catherine Delbaldo; Karina Vera; Veronique Girre; Judy Chiao; Sian Armour; Sheelagh Frame; Simon R Green; Athos Gianella-Borradori; Véronique Diéras; Eric Raymond
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
Ida Iurisci; Elisabeth Filipski; Jens Reinhardt; Stéphane Bach; Athos Gianella-Borradori; Stefano Iacobelli; Laurent Meijer; Francis Lévi
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
K Lacrima; A Valentini; C Lambertini; M Taborelli; Andrea Rinaldi; Emanuele Zucca; Carlo V Catapano; Franco Cavalli; Athos Gianella-Borradori; David E MacCallum; F Bertoni
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Athos Gianella-Borradori (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Christophe Le Tourneau; Sandrine Faivre; Valérie Laurence; Catherine Delbaldo; Karina Vera; Veronique Girre; Judy Chiao; Sian Armour; Sheelagh Frame; Simon R Green; Athos Gianella-Borradori; Véronique Diéras; Eric Raymond
Phase I evaluation of seliciclib (R-roscovitine), a novel oral cyclin-dependent kinase inhibitor, in patients with advanced malignancies.
European journal of cancer (Oxford, England : 1990) 2010;46(18):3243-50.
2006: Ida Iurisci; Elisabeth Filipski; Jens Reinhardt; Stéphane Bach; Athos Gianella-Borradori; Stefano Iacobelli; Laurent Meijer; Francis Lévi
Improved tumor control through circadian clock induction by Seliciclib, a cyclin-dependent kinase inhibitor.
Cancer research 2006;66(22):10720-8.
2005: K Lacrima; A Valentini; C Lambertini; M Taborelli; Andrea Rinaldi; Emanuele Zucca; Carlo V Catapano; Franco Cavalli; Athos Gianella-Borradori; David E MacCallum; F Bertoni
In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(7):1169-76.
2005: David E MacCallum; Jean Melville; Sheelagh Frame; Kathryn Watt; Sian Anderson; Athos Gianella-Borradori; David P Lane; Simon R Green
Seliciclib (CYC202, R-Roscovitine) induces cell death in multiple myeloma cells by inhibition of RNA polymerase II-dependent transcription and down-regulation of Mcl-1.
Cancer research 2005;65(12):5399-407.
2005: Azra J Alvi; Belinda Austen; Victoria J Weston; Christopher Fegan; David E MacCallum; Athos Gianella-Borradori; David P Lane; Mike Hubank; Judith E Powell; wenbin Wei; A Malcolm R Taylor; Paul A H Moss; Tatjana Stankovic
A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival.
Blood 2005;105(11):4484-91.
2005: Peter M Fischer; Athos Gianella-Borradori
Recent progress in the discovery and development of cyclin-dependent kinase inhibitors.
Expert opinion on investigational drugs 2005;14(4):457-77.
2005: Emmanuel Agbottah; Cynthia de la Fuente; Sergei Nekhai; Anna Barnett; Athos Gianella-Borradori; Anne Pumfery; Fatah Kashanchi
Antiviral activity of CYC202 in HIV-1-infected cells.
The Journal of biological chemistry 2005;280(4):3029-42.
2004: Dana Gherardi; Vivette D'Agati; Te-Hua Tearina Chu; Anna Barnett; Athos Gianella-Borradori; Irwin Gelman; Peter J Nelson
Reversal of collapsing glomerulopathy in mice with the cyclin-dependent kinase inhibitor CYC202.
Journal of the American Society of Nephrology : JASN 2004;15(5):1212-22.
2003: Peter M Fischer; Athos Gianella-Borradori
CDK inhibitors in clinical development for the treatment of cancer.
Expert opinion on investigational drugs 2003;12(6):955-70.